271 related articles for article (PubMed ID: 24416322)
1. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
[TBL] [Abstract][Full Text] [Related]
2. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
4. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
6. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
8. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
10. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
11. Altered fecal bile acid composition in active ulcerative colitis.
Sommersberger S; Gunawan S; Elger T; Fererberger T; Loibl J; Huss M; Kandulski A; Krautbauer S; Müller M; Liebisch G; Buechler C; Tews HC
Lipids Health Dis; 2023 Nov; 22(1):199. PubMed ID: 37980492
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study.
Negm M; Bahaa A; Farrag A; Lithy RM; Badary HA; Essam M; Kamel S; Sakr M; Abd El Aaty W; Shamkh M; Basiony A; Dawoud I; Shehab H
BMC Gastroenterol; 2022 Apr; 22(1):203. PubMed ID: 35462542
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
16. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.
Pinto-Lopes P; Afonso J; Pinto-Lopes R; Rocha C; Lago P; Gonçalves R; Tavares De Sousa H; Macedo G; Camila Dias C; Magro F
Inflamm Bowel Dis; 2020 Oct; 26(11):1707-1719. PubMed ID: 31912883
[TBL] [Abstract][Full Text] [Related]
17. Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn's disease.
Budzynska A; Gawron-Kiszka M; Nowakowska-Dulawa E; Spiewak J; Lesinska M; Kukla M; Waluga M; Hartleb M
J Physiol Pharmacol; 2017 Dec; 68(6):859-865. PubMed ID: 29550798
[TBL] [Abstract][Full Text] [Related]
18. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
19. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
[TBL] [Abstract][Full Text] [Related]
20. Is moderate red wine consumption safe in inactive inflammatory bowel disease?
Swanson GR; Tieu V; Shaikh M; Forsyth C; Keshavarzian A
Digestion; 2011; 84(3):238-44. PubMed ID: 21876358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
